Eric Nakakura, MD, PhD University of California, San Francisco
- Status: Completed
- Year(s): 2016
- Research Type: Basic
- Primary Tumor Site: Other
- Area of Inquiry: Models
The lack of reliable, widely-available models is currently a major impediment to the development of new therapies for patients with pancreatic neuroendocrine tumors. This proposal to characterize a patient-derived xenograft will help researchers understand and utilize this exciting new resource. Dr. Nakakura will characterize a patient-derived, xenograft model of pancreatic neuroendocrine cancer and continue efforts to develop and share other neuroendocrine cancer models.
Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.
- City: San Francisco
- State: California
- Grant Duration: 1 years
- Awards: No information
- Sponsor: Margie & Robert E. Petersen Foundation
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.